ADEBRELIMAB (SHR-1316)

Clinical trials for ADEBRELIMAB (SHR-1316) explained in plain language.

Never miss a new study

Get alerted when new ADEBRELIMAB (SHR-1316) trials appear

Sign up with your email to follow new studies for ADEBRELIMAB (SHR-1316), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New combo therapy shows promise for untreatable liver cancer

Disease control Not yet recruiting

This study tests a new treatment for people with advanced liver cancer that cannot be surgically removed. The approach combines a targeted drug (bevacizumab), an immunotherapy (adebrelimab), and two liver-directed procedures (TACE and HAIC) to shrink tumors and control the diseas…

Matched conditions: ADEBRELIMAB (SHR-1316)

Phase: PHASE2 • Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control

Last updated May 26, 2026 07:23 UTC

ADEBRELIMAB (SHR-1316)

Get alerted when new ADEBRELIMAB (SHR-1316) trials appear

New combo therapy shows promise for untreatable liver cancer